INDEMNIFICATION AGREEMENTIndemnification Agreement • August 27th, 2004 • Corus Pharma Inc • Delaware
This Indemnification Agreement (this “Agreement”) is made as of , 200 , by and between Corus Pharma, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
CORUS PHARMA, INC. AMENDED AND RESTATED INFORMATION AND REGISTRATION RIGHTS AGREEMENTInformation and Registration Rights Agreement • August 27th, 2004 • Corus Pharma Inc • Delaware
THIS AMENDED AND RESTATED INFORMATION AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of April 9, 2004, by and among Corus Pharma, Inc., a Delaware corporation (the “Company”), and the undersigned holders of shares of the Company’s Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock listed on the attached Exhibit A, as it may be amended from time to time pursuant to the terms hereof (collectively, the “Investors”).
MASTER SERVICES AGREEMENTMaster Services Agreement • September 15th, 2004 • Corus Pharma Inc • Pharmaceutical preparations
This Master Services Agreement (the “Contract”) is agreed to as of July 24, 2002, by and between Inveresk Clinical Research Limited and Inveresk Research International Limited (hereinafter referred to collectively as “Inveresk”) and Salus Pharma, Inc., a Delaware corporation (hereinafter referred to as “the Sponsor”). Sponsor may from time to time issue one or more Project Assignments to Inveresk (“Project Assignment”). Each Project Assignment will include a study protocol (the “Protocol”) applicable thereto. Inveresk will not begin to render services under the Contract unless and until Sponsor issues a Project Assignment for such services (each set of ordered services being a “Project”). Subject to the terms of this Contract, Inveresk will render the services set forth in Project Assignment(s) accepted by Inveresk in accordance with the applicable Protocol and by the completion dates set forth therein.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH TECHNOLOGY LICENSE CONTRACTCorus Pharma Inc • September 15th, 2004 • Pharmaceutical preparations • Minnesota
THIRD AMENDMENT TO OFFICE LEASEOffice Lease • August 27th, 2004 • Corus Pharma Inc
This THIRD AMENDMENT TO OFFICE LEASE (“Third Amendment”) is made as of July 7, 2003, by and between CONNECTICUT GENERAL LIFE INSURANCE COMPANY, a Connecticut corporation, on behalf of its Separate Account R (“Landlord”), and CORUS PHARMA, INC., a Delaware corporation (“Tenant”). Landlord and Tenant hereinafter may be referred to each as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO OFFICE LEASEOffice Lease • August 27th, 2004 • Corus Pharma Inc
This First Amendment to Office Lease (this “First Amendment”), is made effective the 6th day of Feb. 2002, by and between Connecticut General Life Insurance Company (“Landlord”) and Corus Pharma, Inc. (“Tenant”).
SERVICES AGREEMENTServices Agreement • September 15th, 2004 • Corus Pharma Inc • Pharmaceutical preparations • England
This Services Agreement (the “Contract”) is agreed to as of July 1, 2003 (the “Effective Date”) by and between Inveresk Research International Limited with offices at Tranent, EH33 2NE, Scotland, United Kingdom and its Affiliates (hereinafter referred to as “Inveresk”) and Abaris Pharma, Inc., a Delaware corporation with offices at 2025 First Avenue, Suite 800, Seattle, WA 98121 (hereinafter referred to as the “Sponsor”).
EMPLOYEE CONFIDENTIALITY, INVENTIONS, AND NON-COMPETITION AGREEMENTNon-Competition • August 27th, 2004 • Corus Pharma Inc • Washington
This Agreement is made and entered into as of May , 2001, by and between Corus Pharma, Inc., a Delaware corporation (“Company”) and A. Bruce Montgomery, M.D. (“Employee”).
SETTLEMENT AGREEMENT AND GENERAL RELEASESettlement Agreement and General Release • September 15th, 2004 • Corus Pharma Inc • Pharmaceutical preparations • Washington
SETTLEMENT AGREEMENT AND GENERAL RELEASE, dated September 12, 2002, by and among Corus Pharma, Inc., a Delaware corporation (together with its wholly owned subsidiaries, “Corus”), A. Bruce Montgomery, M.D., an individual (“Montgomery”), Jonathan P. Mow, an individual (“Mow”), Bio-Genetic Ventures, Inc., a Washington corporation (“BGV”) and Peter N. Allison, an individual (“Allison”). Corus, Montgomery, Mow, BGV and Allison are sometimes referred to herein together as the “Parties” and individually as a “Party.”
PHARMACEUTICAL SUPPLY AGREEMENTSupply Agreement • September 15th, 2004 • Corus Pharma Inc • Pharmaceutical preparations • Washington
This Agreement is made as of the date it is signed by both parties (the “Effective Date”), by and between Corus Pharma Inc., a Delaware corporation, with its corporate offices at 2025 1st Avenue, Suite 800, Seattle, Washington 98121, United States of America (“Corus”), and Euticals SpA, doing business at Via Emilia, 99, Frazione San Grato, Lodi (LO) 26900, Italy (“Euticals”).
AMENDMENT TO SUBLEASESublease • August 27th, 2004 • Corus Pharma Inc • Washington
THIS AMENDMENT TO SUBLEASE (“Amendment”), dated December 19, 2002 (the “Effective Date”) is entered into by and between DENDREON CORPORATION, a Delaware corporation (“Dendreon”), and CORUS PHARMA, Inc., a Delaware corporation (“Subtenant”).
FOURTH AMENDMENT TO OFFICE LEASEOffice Lease • August 27th, 2004 • Corus Pharma Inc
This FOURTH AMENDMENT TO OFFICE LEASE (“Fourth Amendment”) is made as of June 4 , 2004, by and between CONNECTICUT GENERAL LIFE INSURANCE COMPANY, a Connecticut corporation, on behalf of its Separate Account R (“Landlord”), and CORUS PHARMA, INC., a Delaware corporation (“Tenant”). Landlord and Tenant hereinafter may be referred to each as a “Party” and collectively as the “Parties.”
ContractEngagement Agreement • October 19th, 2004 • Corus Pharma Inc • Pharmaceutical preparations
DEVELOPMENT AGREEMENT BETWEEN ABARIS PHARMA, INC. AND PARI GMBHDevelopment Agreement • September 15th, 2004 • Corus Pharma Inc • Pharmaceutical preparations • Delaware
This Development Agreement (“Agreement”) effective as of April 3, 2003 (the “Effective Date”), is between PARI GmbH, a German corporation with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany (“PARI”) and Abaris Pharma, Inc., a Delaware corporation with a principal place of business at 2025 1st Avenue, Suite 800, Seattle, Washington 98121, United States (“ABARIS”), a wholly owned subsidiary of Corus Pharma, Inc., a Delaware corporation (“Corus”).
SECOND AMENDMENT TO SUBLEASECorus Pharma Inc • August 27th, 2004 • Washington
THIS SECOND AMENDMENT TO SUBLEASE (“Amendment”), dated July 6, 2003 (the “Effective Date”) is entered into by and between DENDREON CORPORATION, a Delaware corporation (“Dendreon”) and CORUS PHARMA, Inc., a Delaware corporation (“Subtenant”).
SUBLEASESublease • August 27th, 2004 • Corus Pharma Inc
THIS SUBLEASE (“Sublease”), dated September 6, 2002, for reference purposes only, is entered into by and between DENDREON CORPORATION, a Delaware corporation (“Dendreon”) and CORUS PHARMA, a Delaware corporation (“Subtenant”).
DEVELOPMENT AGREEMENT BETWEEN SALUS PHARMA, INC. AND PARI GMBHDevelopment Agreement • September 15th, 2004 • Corus Pharma Inc • Pharmaceutical preparations • Delaware
This Development Agreement (“Agreement”) effective as of February 20, 2002 (the “Effective Date”), is between PARI GmbH, a German corporation with a principal place of business at Moosstrasse 9, D-82319 Starnberg, Germany (“PARI”) and Salus Pharma, Inc., a Delaware corporation with a principal place of business at 2025 1st Avenue, Suite 800, Seattle, Washington 98121, United States (“SALUS”), a wholly owned subsidiary of Corus Pharma, Inc., a Delaware corporation (“Corus”).
Letterhead of Dendreon Corporation]Corus Pharma Inc • August 27th, 2004
SECOND AMENDMENT TO OFFICE LEASEOffice Lease • August 27th, 2004 • Corus Pharma Inc
This SECOND AMENDMENT TO OFFICE LEASE (“Second Amendment”) is made as of Sept. 23rd, 2002, by and between CONNECTICUT GENERAL LIFE INSURANCE COMPANY, a Connecticut corporation, on behalf of its Separate Account R (“Landlord”), and CORUS PHARMA, INC., a Delaware corporation (“Tenant”). Landlord and Tenant hereinafter may be referred to each as a “Party” and collectively as the “Parties.”
ENGAGEMENT AGREEMENTEngagement Agreement • October 19th, 2004 • Corus Pharma Inc • Pharmaceutical preparations • California
This Engagement Agreement (this “Agreement”) is made and entered into as of the 15th day of January, 2004 (the “Effective Date”) by and between Montgomery & Co., LLC (“MONTGOMERY”) and Corus Pharma, Inc., a Delaware corporation (“Client”).
CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • August 27th, 2004 • Corus Pharma Inc • Washington
THIS CHANGE IN CONTROL SEVERANCE AGREEMENT (the “Agreement”) is entered into as of , 2004 (the “Effective Date”), by and between (the “Executive”) and Corus Pharma, Inc., a Delaware corporation (the “Company”).
